Galera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%

Galera Therapeutics, Inc. (NASDAQ:GRTX) shares were down 3.8% during trading on Monday . The company traded as low as $0.15 and last traded at $0.15. Approximately 563,079 shares were traded during trading, a decline of 74% from the average daily volume of 2,196,599 shares. The stock had previously closed at $0.16.

Galera Therapeutics Stock Down 3.8 %

The company has a market capitalization of $8.32 million, a PE ratio of -0.11 and a beta of 2.17. The stock has a 50-day moving average of $0.20 and a 200 day moving average of $0.17.

Hedge Funds Weigh In On Galera Therapeutics

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Galera Therapeutics by 86.8% during the first quarter. BlackRock Inc. now owns 321,292 shares of the company’s stock valued at $765,000 after buying an additional 149,253 shares during the period. Renaissance Technologies LLC bought a new stake in Galera Therapeutics during the first quarter valued at $1,045,000. Virtu Financial LLC bought a new stake in Galera Therapeutics during the first quarter valued at $30,000. Geode Capital Management LLC boosted its stake in Galera Therapeutics by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 174,924 shares of the company’s stock valued at $260,000 after buying an additional 9,273 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Galera Therapeutics during the first quarter valued at $56,000. 50.77% of the stock is currently owned by hedge funds and other institutional investors.

Galera Therapeutics Company Profile

Galera Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.